An object of the present invention is to provide a novel metal-organic framework with a dicarboxylic acid having a terphenyl skeleton as an organic ligand and a gas storage method using such a metal-organic framework. A metal-organic framework comprising a carboxylate ion of formula (I) and a multivalent metal ion bonded to each other. (In formula (I), R.sup.1 and R.sup.2 each independently are a hydroxy group or an unsubstituted or substituted C1-6 alkyl group. R.sup.10 and R.sup.11 each independently are an unsubstituted or substituted C1-6 alkyl group. R.sup.20 is an unsubstituted or substituted C1-6 alkyl group. Provided that, as substituents on R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.10, R.sup.11, and R.sup.20, a carboxy group (COOH) and a carboxylate ion group (COO—) are excluded. In addition, R.sup.10 and R.sup.11 are not a methyl group at the same time.)

##STR00001##

A fluorinated amide compound having a specific repeating unit and a fluorinated nitrogen-containing heterocyclic ring-containing compound having a specific repeating unit.

An object of the present invention is to provide a metal-organic framework capable of adsorbing a gas such as a hydrogen molecule or carbon dioxide at a practical level. The metal-organic framework is used for adsorbing a gas such as hydrogen or carbon dioxide and comprises a multivalent metal ion and a carboxylate ion of formula [I] [wherein in formula [I], X.sup.1 to X.sup.3 each independently represent a functional group of formula [II] (wherein in formula [II], Z is a single bond or a multivalent linking group, k is an integer of 1 to 4, and * is the position at which a bond is formed with a benzene ring); and Y.sup.1 and Y.sup.2 each independently represent a hydrogen atom, a halogeno group, a C1-6 alkyl group or the like, provided that when the multivalent metal ion is a trivalent metal ion, Y.sup.1 and Y.sup.2 each independently represent a halogeno group, a C1-6 alkyl group or the like], wherein the carboxylate ion and the multivalent metal ion are bound to each other.

##STR00001##

A compound of the following structure is provided:

##STR00001##

A compound of the following structure is provided:

##STR00001##

Compounds of formula I and formula II

##STR00001##

their intermediates, as well as processes for the preparation of compounds of formula I and formula II, are disclosed. Use of compounds of formula I for the production of compounds of formula VI

##STR00002##

is also disclosed. Additionally, the use of compounds of formula I or formula II for the production of active compounds is disclosed.

The present invention relates to methods of preparing fused ring indeno compounds that involves reacting together a dienophile and a lactone compound, in the presence of a catalyst, and a carboxylic acid anhydride. With some embodiments, the fused ring indeno compound is represented by the following Formula (I-A), the dienophile is represented by the following Formula (II-A), and the lactone compound is represented by the following Formula (III-A): ##STR00001##

The present invention relates to methods of preparing fused ring indeno compounds that involves reacting together a dienophile and a lactone compound, in the presence of a catalyst, and a carboxylic acid anhydride. With some embodiments, the fused ring indeno compound is represented by the following Formula (I-A), the dienophile is represented by the following Formula (II-A), and the lactone compound is represented by the following Formula (III-A): ##STR00001##

The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C.sub.1-C.sub.6)alkyl or a CN; R1b represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R1c represents H or a (C.sub.1-C.sub.6)alkyl; R2 represents H, an halogen, an OH, an O(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl; R3 represents H, an halogen, a (C.sub.1-C.sub.6)alkyl, an OH, an O(C.sub.1-C.sub.6)alkyl, a CONH.sub.2 or CN; R4 represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C.sub.1-C.sub.6)alkyl, or one of its enantiomers. ##STR00001##

The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C.sub.1-C.sub.6)alkyl or a CN; R1b represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R1c represents H or a (C.sub.1-C.sub.6)alkyl; R2 represents H, an halogen, an OH, an O(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl; R3 represents H, an halogen, a (C.sub.1-C.sub.6)alkyl, an OH, an O(C.sub.1-C.sub.6)alkyl, a CONH.sub.2 or CN; R4 represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C.sub.1-C.sub.6)alkyl, or one of its enantiomers. ##STR00001##